• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

坦索罗辛能强有力且有选择性地拮抗人重组α(1A/1D)-肾上腺素能受体:与α(1A)-肾上腺素能受体缓慢解离可能是其对α(1A)-肾上腺素能受体亚型选择性的原因。

Tamsulosin potently and selectively antagonizes human recombinant α(1A/1D)-adrenoceptors: slow dissociation from the α(1A)-adrenoceptor may account for selectivity for α(1A)-adrenoceptor over α(1B)-adrenoceptor subtype.

机构信息

Applied Pharmacology Research Laboratories, Drug Discovery Research, Astellas Pharma Inc, Miyukigaoka, Tsukuba, Ibaraki 305–8585, Japan.

出版信息

Biol Pharm Bull. 2012;35(1):72-7. doi: 10.1248/bpb.35.72.

DOI:10.1248/bpb.35.72
PMID:22223340
Abstract

We determined the binding affinity of tamsulosin, a selective α(1)-adrenoceptor antagonist, for human α(1)-adrenoceptor subtypes in comparison with those of other α(1)-adrenoceptor antagonists including silodosin, prazosin, 5-methylurapidil, terazosin, alfuzosin, nafopidil, urapidil and BMY7378. The association and dissociation kinetics of [(3)H]tamsulosin for recombinant human α(1)-adrenoceptor subtypes were compared with those of [(3)H]prazosin. Tamsulosin competitively inhibited [(3)H]prazosin binding to human α(1A)-, α(1B)- and α(1D)-adrenoceptors (pK(i) values were 10.38, 9.33, 9.85) indicating 11 and 3.4-fold higher affinities for human α(1A)-adrenoceptor than those for α(1B)- and α(1D)-adrenoceptors, respectively. The affinity of tamsulosin for the human α(1A)-adrenoceptor was, respectively, 5, 9.9, 38, 120, 280, 400, 1200 and 10000 fold higher than those of silodosin, prazosin, 5-methylurapidil, terazosin, alfuzosin, naftopidil, urapidil and BMY7378, respectively. [(3)H]Tamsulosin dissociated from the α(1A)-adrenoceptor slower than from the α(1B)- and α(1D)-adrenoceptors (α(1B)>α(1D)>α(1A)). Moreover, [(3)H]tamsulosin dissociated slower than [(3)H]prazosin from the α(1A)-adrenoceptor and faster from the α(1B)- and α(1D)-adrenoceptors. In conclusion, tamsulosin potently and selectively antagonized α(1A/1D)-adrenoceptor ligand binding, and slowly dissociated from the α(1A)-adrenoceptor subtype.

摘要

我们测定了坦索罗辛(一种选择性的α1-肾上腺素能受体拮抗剂)与其他α1-肾上腺素能受体拮抗剂(如西洛多辛、哌唑嗪、5-甲基育亨宾、特拉唑嗪、阿夫唑嗪、那氟沙星、乌洛他定和 BMY7378)对人α1-肾上腺素能受体亚型的亲和力,并进行了比较。我们比较了 [3H]坦索罗辛与 [3H]哌唑嗪与重组人α1-肾上腺素能受体亚型的结合和解离动力学。坦索罗辛竞争性地抑制了 [3H]哌唑嗪与人类α1A-、α1B-和α1D-肾上腺素受体的结合(pK i值分别为 10.38、9.33 和 9.85),表明其对人类α1A-肾上腺素能受体的亲和力比α1B-和α1D-肾上腺素能受体分别高 11 倍和 3.4 倍。坦索罗辛对人α1A-肾上腺素能受体的亲和力分别比西洛多辛、哌唑嗪、5-甲基育亨宾、特拉唑嗪、阿夫唑嗪、那氟沙星、乌洛他定和 BMY7378高 5、9.9、38、120、280、400、1200 和 10000 倍。[3H]坦索罗辛从α1A-肾上腺素能受体的解离速度比从α1B-和α1D-肾上腺素能受体(α1B>α1D>α1A)的解离速度慢。此外,与α1A-肾上腺素能受体相比,[3H]坦索罗辛从α1B-和α1D-肾上腺素能受体的解离速度更快。总之,坦索罗辛对α1A/1D-肾上腺素能受体配体结合具有强大的选择性拮抗作用,且从α1A-肾上腺素能受体亚型缓慢解离。

相似文献

1
Tamsulosin potently and selectively antagonizes human recombinant α(1A/1D)-adrenoceptors: slow dissociation from the α(1A)-adrenoceptor may account for selectivity for α(1A)-adrenoceptor over α(1B)-adrenoceptor subtype.坦索罗辛能强有力且有选择性地拮抗人重组α(1A/1D)-肾上腺素能受体:与α(1A)-肾上腺素能受体缓慢解离可能是其对α(1A)-肾上腺素能受体亚型选择性的原因。
Biol Pharm Bull. 2012;35(1):72-7. doi: 10.1248/bpb.35.72.
2
Evaluation of the pharmacological selectivity profile of alpha 1 adrenoceptor antagonists at prostatic alpha 1 adrenoceptors: binding, functional and in vivo studies.α1肾上腺素能受体拮抗剂在前列腺α1肾上腺素能受体上的药理选择性概况评估:结合、功能及体内研究
Br J Pharmacol. 1996 Jun;118(4):871-8. doi: 10.1111/j.1476-5381.1996.tb15480.x.
3
Drugs for treatment of benign prostatic hyperplasia: affinity comparison at cloned alpha 1-adrenoceptor subtypes and in human prostate.治疗良性前列腺增生的药物:在克隆的α1-肾上腺素能受体亚型及人前列腺中的亲和力比较
J Auton Pharmacol. 1996 Feb;16(1):21-8. doi: 10.1111/j.1474-8673.1996.tb00352.x.
4
Up-regulation of α1a and α1d-adrenoceptors in the prostate by administration of subtype selective α1-adrenoceptor antagonist tamsulosin in patients with benign prostatic hyperplasia.在良性前列腺增生症患者中,给予亚型选择性α1-肾上腺素受体拮抗剂坦索罗辛可上调前列腺中的α1a 和α1d-肾上腺素受体。
J Urol. 2011 Oct;186(4):1530-6. doi: 10.1016/j.juro.2011.05.048. Epub 2011 Aug 19.
5
Revisiting the Pharmacodynamic Uroselectivity of -Adrenergic Receptor Antagonists.重新探讨 -肾上腺素能受体拮抗剂的药效学尿选择性。
J Pharmacol Exp Ther. 2019 Oct;371(1):106-112. doi: 10.1124/jpet.119.260216. Epub 2019 Jul 8.
6
Comparison of guinea-pig, bovine and rat alpha 1-adrenoceptor subtypes.豚鼠、牛和大鼠α1肾上腺素能受体亚型的比较。
Br J Pharmacol. 1996 Feb;117(4):703-11. doi: 10.1111/j.1476-5381.1996.tb15247.x.
7
[Alpha1-adrenoceptor subtypes and alpha1-adrenoceptor antagonists].[α1-肾上腺素能受体亚型与α1-肾上腺素能受体拮抗剂]
Yakugaku Zasshi. 2006 Mar;126 Spec no.:187-98. doi: 10.1248/yakushi.126.187.
8
Comparative alpha-1 adrenoceptor subtype selectivity and functional uroselectivity of alpha-1 adrenoceptor antagonists.α-1肾上腺素能受体拮抗剂的比较性α-1肾上腺素能受体亚型选择性和功能性尿选择性
J Pharmacol Exp Ther. 1997 Jul;282(1):228-35.
9
Identification of alpha 1-adrenoceptor subtypes in the human prostatic urethra.人前列腺尿道中α1-肾上腺素能受体亚型的鉴定。
Naunyn Schmiedebergs Arch Pharmacol. 1997 Mar;355(3):412-6. doi: 10.1007/pl00004962.
10
Characterization of an alpha 1D-adrenoceptor mediating the contractile response of rat aorta to noradrenaline.介导大鼠主动脉对去甲肾上腺素收缩反应的α1D肾上腺素能受体的特性研究
Br J Pharmacol. 1995 Jul;115(6):981-6. doi: 10.1111/j.1476-5381.1995.tb15907.x.

引用本文的文献

1
generation of dual-target compounds using artificial intelligence.利用人工智能生成双靶点化合物。
iScience. 2024 Dec 17;28(1):111526. doi: 10.1016/j.isci.2024.111526. eCollection 2025 Jan 17.
2
Predicting therapeutic and side effects from drug binding affinities to human proteome structures.从药物与人蛋白质组结构的结合亲和力预测治疗效果和副作用。
iScience. 2024 May 20;27(6):110032. doi: 10.1016/j.isci.2024.110032. eCollection 2024 Jun 21.
3
Semirigid ureteroscopy and tamsulosin therapy as dilatation methods before flexible ureteroscopy: evaluation and benefits.
半刚性输尿管镜检查联合坦索罗辛治疗在软性输尿管镜检查前的扩张作用:评估与获益。
World J Urol. 2024 Feb 8;42(1):75. doi: 10.1007/s00345-023-04696-2.
4
α-Adrenergic Receptors: Insights into Potential Therapeutic Opportunities for COVID-19, Heart Failure, and Alzheimer's Disease.α-肾上腺素能受体:COVID-19、心力衰竭和阿尔茨海默病潜在治疗机会的新见解。
Int J Mol Sci. 2023 Feb 20;24(4):4188. doi: 10.3390/ijms24044188.
5
Preventive effects of tamsulosin for postoperative urinary retention after lower limb arthroplasty: A randomized controlled study.坦索罗辛预防下肢关节置换术后尿潴留的效果:一项随机对照研究。
Investig Clin Urol. 2021 Sep;62(5):569-576. doi: 10.4111/icu.20200523. Epub 2021 Aug 3.
6
Evaluation of Preoperative Tamsulosin Role in Facilitating Ureteral Orifice Navigation for School-Age Pediatric Ureteroscopy.术前坦索罗辛在学龄期小儿输尿管镜检查中辅助输尿管口定位的作用评估
Res Rep Urol. 2020 Nov 16;12:563-568. doi: 10.2147/RRU.S283126. eCollection 2020.
7
Alpha-adrenoceptor antagonist improves underactive bladder associated with diabetic cystopathy via bladder blood flow in rats.α-肾上腺素能受体拮抗剂通过增加大鼠膀胱血流量改善糖尿病性膀胱病伴发的膀胱功能低下。
BMC Urol. 2017 Aug 23;17(1):64. doi: 10.1186/s12894-017-0256-9.
8
Reversible exacerbation of obstructive sleep apnea by α1-adrenergic blockade with tamsulosin: A case report.坦索罗辛α1-肾上腺素能阻滞致阻塞性睡眠呼吸暂停可逆性加重:一例报告
Respir Med Case Rep. 2016 Oct 14;19:181-186. doi: 10.1016/j.rmcr.2016.10.005. eCollection 2016.
9
Personalized therapeutics of α₁-blockers in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia.对提示良性前列腺增生的下尿路症状患者进行α₁受体阻滞剂的个体化治疗。
Clin Interv Aging. 2015 Mar 26;10:621-2. doi: 10.2147/CIA.S82435. eCollection 2015.
10
Identification of two novel α1-AR agonists using a high-throughput screening model.使用高通量筛选模型鉴定两种新型α1-肾上腺素能受体激动剂。
Molecules. 2014 Aug 20;19(8):12699-709. doi: 10.3390/molecules190812699.